1. Home
  2. INLX vs INKT Comparison

INLX vs INKT Comparison

Compare INLX & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INLX
  • INKT
  • Stock Information
  • Founded
  • INLX 1996
  • INKT 2017
  • Country
  • INLX United States
  • INKT United States
  • Employees
  • INLX N/A
  • INKT N/A
  • Industry
  • INLX EDP Services
  • INKT Medicinal Chemicals and Botanical Products
  • Sector
  • INLX Technology
  • INKT Health Care
  • Exchange
  • INLX Nasdaq
  • INKT Nasdaq
  • Market Cap
  • INLX 40.8M
  • INKT 48.7M
  • IPO Year
  • INLX N/A
  • INKT 2021
  • Fundamental
  • Price
  • INLX $9.87
  • INKT $15.98
  • Analyst Decision
  • INLX
  • INKT Buy
  • Analyst Count
  • INLX 0
  • INKT 3
  • Target Price
  • INLX N/A
  • INKT $37.50
  • AVG Volume (30 Days)
  • INLX 2.3K
  • INKT 130.2K
  • Earning Date
  • INLX 08-13-2025
  • INKT 08-14-2025
  • Dividend Yield
  • INLX N/A
  • INKT N/A
  • EPS Growth
  • INLX N/A
  • INKT N/A
  • EPS
  • INLX N/A
  • INKT N/A
  • Revenue
  • INLX $17,127,854.00
  • INKT N/A
  • Revenue This Year
  • INLX $2.47
  • INKT N/A
  • Revenue Next Year
  • INLX $7.72
  • INKT N/A
  • P/E Ratio
  • INLX N/A
  • INKT N/A
  • Revenue Growth
  • INLX N/A
  • INKT N/A
  • 52 Week Low
  • INLX $8.74
  • INKT $4.56
  • 52 Week High
  • INLX $16.50
  • INKT $76.00
  • Technical
  • Relative Strength Index (RSI)
  • INLX 38.26
  • INKT 52.10
  • Support Level
  • INLX $8.98
  • INKT $14.41
  • Resistance Level
  • INLX $10.17
  • INKT $15.66
  • Average True Range (ATR)
  • INLX 0.42
  • INKT 1.63
  • MACD
  • INLX 0.01
  • INKT 0.10
  • Stochastic Oscillator
  • INLX 40.16
  • INKT 66.68

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Share on Social Networks: